Five‐year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence

Pessione, Fabienne; Ramond, Marie-José; Peters, Lars; Pham, Bach-Nga; Batel, Philippe; Rueff, B; Valla, Dominique

doi:10.1034/j.1600-0676.2003.01804.x

Cited by 235 publications

(169 citation statements)

References 32 publications

Supporting

Mentioning

149

Contrasting

Unclassified

Order By: Relevance

“…11,62,68 Underlying aetiology may be a significant factor in this variability, with viral cirrhoses being detected at an earlier stage 69 and patients with cirrhosis of alcoholic origin presenting with more advanced failure. 11,60 Epidemiology and natural history of hepatocellular carcinoma Hepatocellular carcinoma (HCC) is the name given to tumours arising from liver cells (hepatocytes). HCC is considered to be the most common type of primary liver tumour, although data from the office for National Statistics (ONS) show that, in England, intrahepatic bile duct cancer (cholangiocarcinoma) may be more common, 70 certainly among women.…”

Section: Incidence Of Decompensationmentioning

confidence: 99%

Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis

Coon¹,

Rogers²,

Hewson³

et al. 2007

Health Technol Assess

151

108

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. Declared competing interests of authors: K Stein received an unrestricted grant from Schering Plough (UK) to carry out work on the cost-effectiveness of combination therapy for hepatitis C in 2000. KS is also a member of the editorial board for Health Technology Assessment, but he was not involved in the editorial process for this report. M Cramp sits on hepatitis C advisory boards for Schering Plough, Gilead and Roche. He has received unrestricted educational grants from Roche and Schering Plough to support research and service development. He has been awarded an NHS R&D grant looking at injecting drug users who do not have hepatitis C virus infection. J Thompson Coon received a grant from the Hepatitis C Trust to conduct a systematic review of complementary and alternative therapies for the treatment of chronic hepatitis C. HTA Published September 2007This report should be referenced as follows: NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, man...

show abstract

Section: Incidence Of Decompensationmentioning

confidence: 99%

Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis

Coon¹,

Rogers²,

Hewson³

et al. 2007

Health Technol Assess

151

108

View full text Add to dashboard Cite

show abstract

“…High age and continuous alcohol consumption of more than 10 g ethanol per day were independent predictors of a poor prognosis [74]. The prognostic importance of abstinence was demonstrated in both Child-Pugh A/B and Child-Pugh C patients [75].…”

Section: Antifibrotic Therapymentioning

confidence: 88%

Evidence-based clinical practice guidelines for liver cirrhosis 2015

et al. 2016

View full text Add to dashboard Cite

The Japanese Society of Gastroenterology revised the evidence-based clinical practice guidelines for liver cirrhosis in 2015. Eighty-three clinical questions were selected, and a literature search was performed for the clinical questions with use of the MEDLINE, Cochrane, and Igaku Chuo Zasshi databases for the period between 1983 and June 2012. Manual searching of the latest important literature was added until August 2015. The guidelines were developed with use of the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. This digest version in English introduces selected clinical questions and statements related to the management of liver cirrhosis and its complications. Branched-chain amino acids relieve hypoalbuminemia and hepatic encephalopathy and improve quality of life. Nucleoside analogues and peginterferon plus ribavirin combination therapy improve the prognosis of patients with hepatitis B virus related liver cirrhosis and hepatitis C related compensated liver cirrhosis, respectively, although the latter therapy may be replaced by direct-acting antivirals. For liver cirrhosis caused by primary biliary cirrhosis and active autoimmune hepatitis, urosodeoxycholic acid and steroid are recommended, respectively. The most adequate modalities for the management of variceal bleeding are the endoscopic injection sclerotherapy for esophageal varices and the balloon-occluded retrograde transvenous obliteration following endoscopic obturation with cyanoacrylate for gastric varices. Beta-blockers are useful for primary prophylaxis of esophageal variceal bleeding. The V 2 receptor antagonist tolvaptan is a useful add-on therapy in careful diuretic therapy for ascites. Albumin infusion is useful for the prevention of paracentesis-induced circulatory disturbance and renal failure. In addition to disaccharides, the nonabsorbable antibiotic rifaximin is useful for the management of encephalopathy. Anticoagulation therapy is proposed for patients with acute-onset or progressive portal vein thrombosis.

show abstract

“…Three factors greatly condition the long-term prognosis of AH that are scarcely emphasized in the paper by Bargalló et al These include alcohol withdrawal, presence of cirrhosis, and response to steroid therapy. Withdrawal is the single most important predictor in AH once the initial stage is over, and is also essential when considering transplantation (19). Therefore, dependency therapy should be initiated during hospitalization to be followed by stringent monitoring for at least two years after discharge.…”

Section: Establishing Prognosis In Alcoholic Hepatitismentioning

confidence: 99%

Establishing prognosis in alcoholic hepatitis

Caballería

2013

Rev. esp. enferm. dig.

View full text Add to dashboard Cite

Five‐year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence

Cited by 235 publications

References 32 publications

Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis

Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis

Evidence-based clinical practice guidelines for liver cirrhosis 2015

Establishing prognosis in alcoholic hepatitis

Contact Info

Product

Resources

About